Cargando…

Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome

Iron chelation therapy is often used to treat iron overload in patients requiring transfusion of red blood cells (RBC). A 76-year-old man with MDS type refractory cytopenia with multilineage dysplasia, intermediate-1 IPSS risk, was referred when he became transfusion dependent. He declined infusiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Badawi, Maha A., Vickars, Linda M., Chase, Jocelyn M., Leitch, Heather A.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846339/ https://www.ncbi.nlm.nih.gov/pubmed/20368773 http://dx.doi.org/10.1155/2010/164045

Ejemplares similares

Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
por: Kochhar, Harpreet, et al.
Publicado: (2015)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy
por: Pinto, Valeria, et al.
Publicado: (2015)

Clinical view versus guideline adherence in ferritin monitoring and initiating iron chelation therapy in patients with myelodysplastic syndromes
por: Rozema, Johanne, et al.
Publicado: (2022)

Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
por: Jang, Jun Ho, et al.
Publicado: (2013)

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
por: Gattermann, Norbert
Publicado: (2008)

Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia
por: Bou-Fakhredin, Rayan, et al.
Publicado: (2017)

Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
por: Parisi, Sarah, et al.
Publicado: (2021)

Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
por: Motta, Irene, et al.
Publicado: (2020)

Role of iron chelation in improving survival: An integral part of current therapy for myelodysplastic syndromes
por: Taran, Sachi Jain, et al.
Publicado: (2015)

Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome
por: Singhal, Deepak, et al.
Publicado: (2017)

Barriers to adherence to iron chelation therapy among adolescent with transfusion dependent thalassemia
por: Mohamed, Rafaa, et al.
Publicado: (2022)

Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea
por: Lee, Jong Wook
Publicado: (2008)

Optimizing Communication and Adherence to Iron Chelation Therapy From Diagnosis to Treatment in Patients With Myelodysplastic Syndromes
por: Shah, Jayshree, et al.
Publicado: (2016)

Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion
por: Veríssimo, Monica Pinheiro de Almeida, et al.
Publicado: (2013)

Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
por: Saliba, Antoine N, et al.
Publicado: (2015)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload
por: Origa, Raffaella, et al.
Publicado: (2022)

Prevalence of iron deficiency and red blood cell transfusions in surgical patients
por: Tonino, Rik Paulus Bernardus, et al.
Publicado: (2021)

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
por: Hoeks, Marlijn, et al.
Publicado: (2020)

Management of patients with lower-risk myelodysplastic syndromes
por: Brunner, Andrew M., et al.
Publicado: (2022)

Rapid iron loading in a pregnant woman with transfusion-dependent thalassemia after brief cessation of iron chelation therapy
por: Farmaki, Kallistheni, et al.
Publicado: (2008)

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome
por: de Montalembert, Mariane, et al.
Publicado: (2017)

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
por: de Swart, Louise, et al.
Publicado: (2020)

Iron Chelation in Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms—Real-World Data from the German Noninterventional Study EXCALIBUR
por: Schulz, Felicitas, et al.
Publicado: (2023)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era
por: Ambler, Kimberley L. S., et al.
Publicado: (2012)

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

Myelodysplastic Syndrome with Transfusion Dependence Treated with Venetoclax
por: Jehangir, Waqas, et al.
Publicado: (2020)

Transfusion of platelets, but not of red blood cells, is independently associated with nosocomial infections in the critically ill
por: Engele, Leo J., et al.
Publicado: (2016)

Red blood cell transfusion Results
por: Miadda, R, et al.
Publicado: (2013)

Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome
por: Williamson, Bradley T., et al.
Publicado: (2016)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
por: Kontoghiorghe, Christina N, et al.
Publicado: (2016)

Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
por: Hassan, Mohamed Abdel Malik, et al.
Publicado: (2016)

Red Blood Cell Transfusion
por: West, F. Bernadette, et al.
Publicado: (2015)

Iron Chelation in Local Infection
por: Scott, Cassidy, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pptcs1gbm65thdrnudt3p16oqt